What is he best known for?
The fields of study he is best known for:
- Gene
- Cancer
- Internal medicine
His main research concerns Leukemia, Cancer research, Myeloid leukemia, Immunology and Myeloid.
The concepts of his Leukemia study are interwoven with issues in Fluorescence in situ hybridization, Stem cell and Gene mutation.
His Cancer research research is multidisciplinary, incorporating elements of Germline mutation, Cellular differentiation, Oncogene, CEBPA and Myeloid-Lymphoid Leukemia Protein.
His Myeloid leukemia research includes elements of Bioinformatics, Mutation, Minimal residual disease, Myelodysplastic syndromes and NPM1.
The various areas that Lars Bullinger examines in his Immunology study include Internal medicine, Oncology and Gene expression profiling.
His study in the field of [email protected] is also linked to topics like Untreated Chronic Lymphocytic Leukemia.
His most cited work include:
- Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia (2729 citations)
- Genomic Classification and Prognosis in Acute Myeloid Leukemia (1566 citations)
- Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia (1309 citations)
What are the main themes of his work throughout his whole career to date?
Lars Bullinger focuses on Myeloid leukemia, Cancer research, Leukemia, Internal medicine and Oncology.
His research in Myeloid leukemia intersects with topics in Myeloid, Gene, NPM1 and Gene expression profiling.
His Gene expression profiling study combines topics in areas such as DNA microarray and Bioinformatics.
His Cancer research study incorporates themes from Progenitor cell, Haematopoiesis, Stem cell, Gene expression and microRNA.
His research brings together the fields of Bone marrow and Leukemia.
His Internal medicine study frequently links to related topics such as Gene mutation.
He most often published in these fields:
- Myeloid leukemia (39.30%)
- Cancer research (34.91%)
- Leukemia (27.54%)
What were the highlights of his more recent work (between 2017-2021)?
- Cancer research (34.91%)
- Myeloid leukemia (39.30%)
- Internal medicine (25.96%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Cancer research, Myeloid leukemia, Internal medicine, Oncology and Myeloid.
As a member of one scientific family, Lars Bullinger mostly works in the field of Cancer research, focusing on T cell and, on occasion, CD8.
Specifically, his work in Myeloid leukemia is concerned with the study of Midostaurin.
His Transplantation, Cumulative incidence, Disease and Hematopoietic stem cell transplantation study in the realm of Internal medicine connects with subjects such as In patient.
Lars Bullinger studied Oncology and Gene mutation that intersect with Cytogenetics and Cytarabine.
In his study, which falls under the umbrella issue of Myeloid, Synthetic lethality is strongly linked to Leukemia.
Between 2017 and 2021, his most popular works were:
- Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial (127 citations)
- Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. (101 citations)
- Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. (101 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Cancer
- Internal medicine
Myeloid leukemia, Myeloid, Cancer research, Leukemia and Internal medicine are his primary areas of study.
His Myeloid leukemia research is multidisciplinary, incorporating perspectives in Chromatin, Cell cycle, Regulation of gene expression and Gene.
His studies deal with areas such as Haematopoiesis, Epigenetics, Disease and Bone marrow as well as Myeloid.
He has included themes like Synthetic lethality, DNA repair, Progenitor cell, Stem cell and Transcriptome in his Cancer research study.
The study incorporates disciplines such as Receptor tyrosine kinase and Downregulation and upregulation in addition to Leukemia.
His Internal medicine research incorporates elements of Genotyping and Oncology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
